Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 5Not yet recruiting 1

Sponsor Class

OTHER 9INDUSTRY 6

Study Type

Observational 4Interventional 2

Sponsor

Cancer Type

Genitourinary 13Gastrointestinal 9Breast 9Other hematologic neoplasm 7Thoracic 6Plasma cell 6Lymphoid 5Tumor-Agnostic 4Head & Neck 4Gynecologic 4CNS 4Dermatologic 2Sarcoma 1Other solid neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 6Neoplasms, Plasma Cell 3

Interventions

Dexamethasone 315Bortezomib 166Lenalidomide 132pomalidomide 113daratumumab 96carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Standard of Care × Plasma cell × Clear all
NCT07181239 2025-09-18

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

Keymed Biosciences Co.Ltd

Phase 3 Not yet recruiting
280 enrolled
Plasma cell

Multiple Myeloma

NCT01711671 2025-08-03

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Leap Therapeutics, Inc.

Phase 1 Completed
8 enrolled
Plasma cell

Multiple Myeloma

NCT06504524 2025-06-27

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Pfizer

Completed
633 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06592222 2025-05-20

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Pfizer

Completed
4 enrolled
Plasma cell

Multiple Myeloma

NCT05932290 2024-10-29

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Pfizer

Completed
514 enrolled 16 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05565391 2024-05-21

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Pfizer

Completed
508 enrolled 16 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡